Evaluation for Genetic Disorders in the Absence of a Clinical Indication for Testing: Elective Genomic Testing.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
01 2019
Historique:
received: 06 06 2018
revised: 29 08 2018
accepted: 17 09 2018
pubmed: 20 11 2018
medline: 19 6 2020
entrez: 20 11 2018
Statut: ppublish

Résumé

The increasing quality and diminishing cost of next-generation sequencing has transformed our ability to interrogate large quantities of genetic information. This has led to a dramatic increase in the number of elective genomic tests performed. In this article, elective test denotes a test that a patient chooses to undertake without a clinical indication. The variety of elective genomic testing options is considerable. Because these offerings provide differing levels of sensitivity and specificity, it can be difficult to choose among them. A simple rubric to compare offerings is not readily available. We propose a framework designated completeness that evaluates both analytical and interpretative components of genomic tests. We then illustrate how this framework can be used to evaluate the expanding landscape of elective genomic testing.

Identifiants

pubmed: 30453057
pii: S1525-1578(18)30199-5
doi: 10.1016/j.jmoldx.2018.09.006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-12

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

James T Lu (JT)

Helix, San Carlos, California.

Matthew Ferber (M)

Mayo Clinic Laboratories, Rochester, Minnesota.

Jill Hagenkord (J)

Color Genomics Inc., Burlingame, California.

Elissa Levin (E)

Helix, San Carlos, California.

Sarah South (S)

AncestryDNA, Lehi, Utah.

Hyunseok P Kang (HP)

Counsyl Inc., South San Francisco, California.

Kimberly A Strong (KA)

HudsonAlpha Institute for Biotechnology, Huntsville, Alabama.

David P Bick (DP)

HudsonAlpha Institute for Biotechnology, Huntsville, Alabama. Electronic address: dbick@hudsonalpha.org.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH